期刊文献+

高敏感心肌肌钙蛋白T检测方法在诊断急性心肌梗死中的价值 被引量:45

Clinical application of high-sensitivity cardiac troponin T assay in the diagnosis of acute myocardial infarction
原文传递
导出
摘要 目的 评价hs-cTnT在AMI诊断中的临床应用价值.方法 比较147例确诊AMI患者(其中122例为NSTEMI患者)入院即刻样本hs-cTnT、con-cTnT检出阳性率.检测481例胸痛患者入院5个不同时间点(入院即刻和入院后4、12、20和28 h)血清样本的hs-cTnT、con-cTnT、CKMB mass和MYO浓度,比较确诊AMI患者各指标不同时间点的检出阳性率.依据ROC曲线分析比较各心脏标志物对AMI的诊断特性.动态监测比较AMI组、非AMI心脏疾病组、AMI相关高危疾病组和表面健康对照组入院4 h内hs-cTnT浓度变化率.结果 确诊AMI和NSTEMI患者人院即刻hs-cTnT的检出阳性率分别为90.3%和91.0%,明显高于con-cTnT的61.9%和60.6%(x2值分别为23.08、18.64,P均<0.01).人院各时间点不同指标(hs-cTnT、con-cTnT、CKMB mass和MYO)检测中,hs-cTnT检出阳性率最高为100%(入院4 h后),con-cTnT最高为99.2%(入院12 h后),CKMB mass最高为92.1%(入院12 h后),MYO最高为74%(人院4 h后).hs-cTnT、con-cTnT、CKMB mass和MYO入院即刻的ROC曲线下面积(AUC)分别为0.935、0.851、0.827和0.769,hs-cTnT与con-cTnT、CKMB mass和MYO之间AUC差异均有统计学意义(Z1=3.13,Z2=4.46,Z3=5.62,P均<0.05).动态监测AMI组变化率与其他3组变化率分别为203.03%(25.00%~2036.40%)、0.00%(-3.48%~5.21%)、0.00%(-1.17%~2.00%)、-1.97%(-3.83%~0.007%),差异有统计学意义(x2=166.09,P<0.01).结论 相比con-cTnT,hs-cTnT检测能够为AMI的更早期诊断提供可靠依据,减少NSTEMI患者的误诊或漏诊.单点hs-cTnT判断值结合动态监测变化明显优于仅仅使用单点判断值,hs-cTnT判断值结合动态监测变化的诊断特性明显优于单独使用判断值,有助于鉴别诊断因hs-cTnT检测灵敏度提高而增多的疑似AMI患者.由于具有良好的诊断特性,hs-cTnT检测可能使一些"早期标志物"的应用空间大大缩小. Objective To evaluate the clinical application of hs-cTnT in diagnosis of AMI. Methods The detectable rates of hs-cTnT and con-cTnT from 147 AMI ( including 122 NSTEMI )patients on immediate admission were compared. The related biological markers including hs-cTnT, con-cTnT, CKMB mass and MYO were determined for all samples from 481 patients with chest pain on immediate admission and 4 h, 12 h ,20 h and 28 h after admission. The receiver operating characteristic curve was used to evaluate the sensitivity and specificity of all markers. The change rates of hs-cTnT within 4 hours from AMI group, non-AMI heart disease group, AMI related high risk disease group and control group were compared with serial detection. Results The detection rates of hs-cTnT for AMI and NSTEMI patients were 90. 3% and 91.0%, and both were significantly higher than the rates of con-cTnT, which were 61.9% and 60. 6% (x2 =23.08,18. 64,all P〈0. 01 ). Among different makers obtained from different collecting times,hs-cTnT had the highest detection rate. For admission cases, the area under curve of hs-cTnT, con-cTnT,CKMB mass and MYO were 0.935, 0.851, 0.827 and 0.769 respectively, and the differences have statistical significance(Z1 = 3. 13, Z2 = 4. 46, Z3 = 5.62, all P 〈 0. 05 ). Besides, there was a significant difference between the change rate of hs-cTnT of AMI and other groups (x2=166.09,P〈0. 01).Conclusions In comparison with con-cTnT, hs-cTnT could provide reliable results for earlier diagnosis of AMI, and could also reduce misdiagnosis and missed diagnosis of NSTEMI. Combining single test of hs-cTnT with serial tests was superior to using cut-off value alone in diagnosis. Moreover, it could be helpful to distinguish non-AMI patients from true AMI patients due to the improved detection sensitivity. Because of its good diagnostic performance, hs-cTnT test may limit the application value of some other "early markers".
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2010年第9期825-830,共6页 Chinese Journal of Laboratory Medicine
基金 基金项目:上海市科委科研计划项目(08411960400)
关键词 肌钙蛋白T 心肌梗死 诊断技术和方法 评价研究 Troponin T Myocardial infarction Diagnostic techniques and procedures Evaluation studies
  • 相关文献

参考文献15

  • 1Hoenig MR,Doust JA,Aroney CN,et al.Early invasive versus conservative strategies for unstable angina & non ST-elevation myocardial infarction in the stent era.Cochrane Database Syst Rev,2006,3:CD004815.
  • 2Wang K,Asinger RW,Marriott HJ.ST-segment elevation in conditions other than acute myocardial infarction.N Engl J Med,2003,349:2128-2135.
  • 3Antman EM,Anbe DT,Armstrong PW,et al.ACC/AHAguidelines for the management of patients with ST-elevation myocardial infarction:a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction).Circulation,2004,110:e82-292.
  • 4潘柏申,杨振华,吴健民.冠状动脉疾病和心力衰竭时心脏标志物临床检测应用建议[J].中华检验医学杂志,2006,29(9):774-778. 被引量:73
  • 5Thygesen K,Alpert JS,White HD,et al.Universal definition of myocardial infarction.JACC,2007,50:2173-2195.
  • 6Thygesen K,Alpert JS,White HD,et al.Myocardial Infarction Redefined-A Consensus Document of The Joint European Society of Cardiology/American College of Cardiology Committee for theRedefinition of Myocardial Infarction.JACC,2000,36:959-969.
  • 7Giannitsis E,Kurz K,Hallermayer K,et al.Analytical validation of a high-sensitivity cardiac troponin T assay.Clin Chem,2010,56:254-261.
  • 8Katus HA,Remppis A,Looser S,et al.Enzyme linked immunoassay of cardiac troponin T for the detection of acute myocardial infarction in patients.Mol Cell Cardiol,1989,21:1349-1353.
  • 9Katus HA,Scheffold T,Remppis A,et al.Proteins of the troponin complex.Lab Med,1992,23:311-317.
  • 10Kontos MC,Fritz LM,Anderson FP,et al.Impact of the troponin standard on the prevalence of acute myocardial infarction.Am Heart J,2003,146:446-452.

二级参考文献33

  • 1Pearson TA, Mensah GA, Hong Y, et al. CDC/AHA Workshop on markers of inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice : Overview. Circulation, 2004,110 : e543-544.
  • 2Myers GL,Rifai N,Tracy RP,et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease : Application to Clinical and Public Health Practice: report from the laboratory science discussion group. Circulation ,200d, 110 :e545-549.
  • 3Smith SC Jr, Anderson JL, Cannon RO 3rd, et al. CDC/AHA Workshop on Markers of inflammation and Cardiovascular Disease:Application to Clinical And Public Health Practice: report from the clinical practice discussion group. Circulation,2004, 110 : e550-553.
  • 4Fortmann SP, Ford E, Criqui MH, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease : Application to Clinical and Public Health Practice: report from the population science discussion group. Circulation,2004, 110 : e554-559.
  • 5Biasucci LM, CDC, AHA. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease : Application to Clinical and Public Health practice: clinical use of inflammatory markers in Patients with cardiovascular diseases : a background paper.Circulation ,2004, 110 :e560-567.
  • 6Wilson PW, CDC, AHA. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease:Application to Clinical and Public Health Practice: ability of inflammatory markers to predict disease in asymptomatic patients: a background paper. Circulation,2004,110:e568-571.
  • 7Roberts WL, CDC, AHA. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease. Application to Clinical and Public Health Practice. laboratory tests available to assess inflammation-performance and standardization: a background paper.Circulation, 2004,110 :e572-578.
  • 8Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation, 2003,108:250-252.
  • 9Apple FS. Clinical and analytical standardization issues confronting cardiac troponin I. Clin Chem, 1999,45:18-20.
  • 10Alpert JS. Defining myocardial infarction:" will the real myocardial infarction please stand up ?" Am Heart J, 2003,146 : 377-379.

共引文献72

同被引文献467

引证文献45

二级引证文献273

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部